Immuneering

About Immuneering

Immuneering Corporation operates as a clinical-stage biopharmaceutical company, directing its efforts toward the development of medicines for a range of oncologic and neurologic diseases. Founded in 2008 by Ben Zeskind, Brett Hall, and Forest White, the company leverages its deep expertise in translational bioinformatics to inform every step of the drug development process. The founding team's background is rooted in biological engineering and computer science from the Massachusetts Institute of Technology (MIT), where they recognized the potential of systems biology and bioinformatics to decipher complex disease mechanisms. This foundation led to the creation of a disease-agnostic platform that utilizes human data to identify and advance therapeutic candidates.

The company's business model centers on creating a wholly owned pipeline of drug candidates. After initially operating as a profitable bioinformatics services company for over a decade, providing analysis to large pharmaceutical firms, Immuneering shifted its strategy to focus on its internal drug development. This strategic pivot was financed by its earlier service-based revenues and culminated in a successful Initial Public Offering (IPO) in July 2021, which provided substantial capital to advance its clinical programs. The company targets the oncology market, specifically focusing on solid tumors driven by mutations in signaling pathways like MAPK and mTOR. Its clients are the patients suffering from these debilitating diseases, with the ultimate customers being healthcare providers and hospital systems.

Immuneering's lead product candidate is IMM-1-104, a selective dual-MEK inhibitor intended for patients with advanced solid tumors characterized by RAS or RAF mutations. This drug is designed to overcome innate resistance by targeting the MAPK pathway more effectively, potentially offering a new treatment paradigm for a broad patient population. Beyond IMM-1-104, which is currently in clinical trials, the company's pipeline includes six other oncology programs and two neuroscience programs in the discovery phase, all stemming from its proprietary computational platform.